Navigation Links
Frost & Sullivan Honors ConforMIS for Its Contribution to Personalized Care Through its Customized Implant Development Technologies
Date:8/18/2008

p>Each year, Frost & Sullivan presents this award to the company that has introduced truly innovative products, practices, or ideas to the specified industry or segment. The company's innovative contribution(s) to healthcare make it possible to envision a new level of care in the diagnosis, treatment, and management of disease, leading to better outcomes and quality-of-life for patients. In addition, the company's innovative efforts may also lead to improvements in the tools that clinicians, diagnosticians, researchers, and healthcare administrators have at their disposal to improve quality and efficiency in provision of healthcare services.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About ConforMIS

ConforMIS, Inc. is a privately held company that develops and commercializes medical devices for the treatment of osteoarthritis and joint damages. The Company's novel and scaleable 'image-to-implant' process is comprised of two related technology platforms. iFit(TM) Technology enables the creation of conforming, patient-specific implants that are precisely sized and shaped to match the 3D topography of the patient's anatomy. iJig(TM) Instrumentation enables the creation of disposable, easy-to-use instrumentation that simplifies the surgical process and improves reproducibility.

To date, ConforMIS has developed a comprehensive line of minimally traumatic, bone and cartilage-preserving knee implants and instrumentation designed to address all stages of osteoarthritis. Each of these devices has been cleared by the US Food a
'/>"/>

SOURCE Frost & Sullivan
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Frost & Sullivan Recognizes Waters Corporation for Its Pioneering, High Customer Value Analytical Instrumentation Product, SYNAPT HDMS
2. Direct From Beijing, 2008 Olympic Gymnastic Superstars and Grammy Award Winning Icons Descend Upon San Diego to Tape ABC Network Womens Cancer Awareness Special, Frosted Pink With A Twist
3. Kingfisher Healthcare (KFH) Wins Prestigious Frost & Sullivan Best Practices Award
4. Olympic Champion Mary Lou Retton and ASCO Join Frosted Pink with a Twist to Empower Women Through Education and Advocacy
5. Draeger Receives Frost & Sullivan Consumer Award for Respiratory Protection
6. Therapy Could Save Limbs After Frostbite
7. Help Your Kids Earn an A for Attentiveness with a Bowl of Frosted Mini- Wheats(R) Cereal for Breakfast
8. Accurays CyberKnife System Receives 2008 North American Medical Devices Product of the Year Award From Frost & Sullivan
9. Nancy Frost Joins Lawson-Hawks as Employee Benefits Vice President
10. MedApps Receives Prestigious Frost & Sullivan Award
11. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)... promotes self-assurance, research finds , ...r may have been right when she told you to sit up ...could make you feel more confident about your thou...p straight gives a good impression to other people...chology professor at Ohio State University, said i...
(Date:11/8/2009)...ire-USNewswire/ -- Speaker Nancy Pelosi and Democr... House passage of H.R. 3962, the Affordable Health...of 220 to 215. Below are the Speaker,s opening re...ceived a call from the President of the United Sta...ctory for the American people. I thank the Preside...
(Date:11/8/2009)...drying of biopharmaceuticals to be available at th... , Toronto, ON (PRWEB) Nov... of Therapure Biopharma Inc. today announced that ...le pharmaceutical grade freeze dryer and expects t...ion) available for contract manufacturing of bioph...
(Date:11/8/2009)... the battle is won," said Dr. Charmaine Yoest. ,...In a vote of 240-194, the Stupak-Ellsworth-Pitts-K...bit abortion mandates and funding in HR 3962 passe...ife Action President and CEO Dr. Charmaine Yoest s...or the pro-life Americans across this country who ...
(Date:11/8/2009)... H.R. 3961 to Secure the Stability of Medicare ,...tement Attributable to: J. James Rohack, M.D., Pre... http://www.newscom.com/cgi-bin/prnh/20081209/AM...House health reform bill, which will help improve ...calls for swift passage of H.R. 3961 to secure the...
Breaking Medicine News(10 mins):Health News:Good Posture May Inspire Confidence 2Health News:Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer 2Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2
...ame of a Class 10 correspondence course student in...iled to do, an official said Saturday//. The ...d 22 students of various private and government hi...at had three others with the same score. The boy h...
...sights about how a bacterium uses different recept...a are sensitive to minute changes in environments ...of 1 drop in a pool of 1,000 drops. New Corn...perative lattice on a bacterium's surface to ampli...
... essential for proper embryo development and disor...h defects such as cleft palate, spina bifida, repo...ffort of the University of Colorado, Health Scienc...Critical for Downregulation of E-Cadherin During M...
...announced a warning on the usage of Triaminic vapo...serious effects //they could have if accidentally ...h authorities have explained that life-threatening...ised as a cough suppressant for kids 2 years of ag...
...fter eating (traditionally called European siesta)... happening due to changes in glucose levels//. ...y in humans and as well as in animals become switc...sed from the neurons, whose action is focused on t...
...er treatment drug has proved so well in the drug t...ght be made //available to patients in the late st...the regulators. It is speculated that Europe... claim that unlike Roche's $1.8bn-a-year drug, Her...
Other Medicine News:Health News:Study Highlights How Bacteria Respond To Changes In Environment 2Health News:GSK’s New Anticancer Drug A Huge Success In Drug trail 2
(Date:11/6/2009)...TA, Nov. 6 GeoVax Labs,...e Company"), an Atlanta-based, biopharmaceutical c...ed by HIV-1 (Human Immunodeficiency Virus) and oth...arter 2009 financial results and provided an opera...ent and Chief Executive Officer commented, "We are...
(Date:11/6/2009)...IEGO, Nov. 6 California American W...s "No Drugs Down the Drain" week for its San Diego...n sponsored by public and private agencies alike t...l pollution in our source water supplies. ,, Ca...rs are encouraged to drop off expired or unwanted ...
(Date:11/5/2009)...IEGO, Nov. 5 Althea Technologies,...acturing services for biopharmaceutical products a...velopment to the company,s platform of services, w...ames Matsuura, Director of Formulation Development...ation and analytical scientists, along with new la...
Breaking Medicine Technology:GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29 2009 5323 1Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29 2009 5323 2Hutchinson Center scientists net 2416 7 million for stem cell research 59136 1Hutchinson Center scientists net 2416 7 million for stem cell research 59136 2Elderly immune system needs a boost 59134 1Elderly immune system needs a boost 59134 2
... 12 Boston,Scientific Corporation (NYSE: BSX ) t...7,500 patients from its TAXUS ARRIVE 1 and 2 regis...ce of the TAXUS(R) Express2(TM),Paclitaxel-Eluting...,two-year pooled ARRIVE data showed that the TAXUS...h diabetes as effectively as in patients without,d...
...entific,Corporation (NYSE: BSX ) today announced ...ss announcements at the Cardiovascular Research Fo...rdiovascular Therapeutics (TCT),scientific symposi..., D.C., Boston Scientific will be announcing a wi...R) Express2(TM) and second-generation TAXUS(R),Lib...
Other Medicine Technology:TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 2Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 3Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 4Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 5Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 6
... disease ELISA products make us a leader in this f...egration into the busy laboratory, our Infectious ...ty and run-to-run consistency. Our Infectious Dise...for a wide range of serological assays including T...
... disease ELISA products make us a leader in this f...egration into the busy laboratory, our Infectious ...ty and run-to-run consistency. Our Infectious Dise...for a wide range of serological assays including T...
... disease ELISA products make us a leader in this f...egration into the busy laboratory, our Infectious ...ty and run-to-run consistency. Our Infectious Dise...for a wide range of serological assays including T...
Giardia lamblia II EIA
Medicine Products: